128 related articles for article (PubMed ID: 25172669)
21. Laboratory monitoring of the non-vitamin K oral anticoagulants.
Blann AD; Lip GY
J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
[No Abstract] [Full Text] [Related]
22. Dental implications of new oral anticoagulants for atrial fibrillation.
Curtin C; Hayes JM; Hayes J
Dent Update; 2014; 41(6):526-8, 530-1. PubMed ID: 25195485
[TBL] [Abstract][Full Text] [Related]
23. Rivaroxaban as an effective treatment for recurrent superficial thrombophlebitis related to primary antiphospholipid syndrome.
Bachmeyer C; Elalamy I
Clin Exp Dermatol; 2014 Oct; 39(7):840-1. PubMed ID: 25186062
[No Abstract] [Full Text] [Related]
24. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
Goto S; Zhu J; Liu L; Oh BH; Wojdyla DM; Aylward P; Bahit MC; Gersh BJ; Hanna M; Horowitz J; Lopes RD; Wallentin L; Xavier D; Alexander JH;
Am Heart J; 2014 Sep; 168(3):303-9. PubMed ID: 25173541
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
[TBL] [Abstract][Full Text] [Related]
26. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation.
Lu Y; Branstad R; Karim RM; Asinger RW
J Clin Pharm Ther; 2014 Dec; 39(6):628-36. PubMed ID: 25252149
[TBL] [Abstract][Full Text] [Related]
27. A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?
Yang E
Vasc Health Risk Manag; 2014; 10():507-22. PubMed ID: 25187724
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Korostelev M; Bihan K; Ferreol L; Tissot N; Hulot JS; Funck-Brentano C; Zahr N
J Pharm Biomed Anal; 2014 Nov; 100():230-235. PubMed ID: 25173108
[TBL] [Abstract][Full Text] [Related]
30. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Ho CW; Ho MH; Chan PH; Hai JJ; Cheung E; Yeung CY; Lau KK; Chan KH; Lau CP; Lip GY; Leung GK; Tse HF; Siu CW
Stroke; 2015 Jan; 46(1):23-30. PubMed ID: 25406148
[TBL] [Abstract][Full Text] [Related]
31. Target-specific oral anticoagulants: practice issues for the clinician.
Plitt A; Giugliano RP
Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406
[TBL] [Abstract][Full Text] [Related]
32. Additional events in the RE-LY trial.
Connolly SJ; Wallentin L; Yusuf S
N Engl J Med; 2014 Oct; 371(15):1464-5. PubMed ID: 25251519
[No Abstract] [Full Text] [Related]
33. Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
Pollack CV; Levy JH; Eikelboom J; Weitz JI; Sellke FW; Huisman MV; Steiner T; Kamphuisen P; Bernstein RA
Am J Emerg Med; 2014 Nov; 32(11):1433-4. PubMed ID: 25239691
[No Abstract] [Full Text] [Related]
34. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
35. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Cuker A; Siegal DM; Crowther MA; Garcia DA
J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
[TBL] [Abstract][Full Text] [Related]
36. Once-daily edoxaban: a safer option than well-managed warfarin for patients with atrial fibrillation?
Giugliano RP
Eur Heart J; 2014 Jul; 35(28):1826-7. PubMed ID: 25184175
[No Abstract] [Full Text] [Related]
37. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
Gorczyca-Michta I; Wożakowska-Kapłon B
Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
[TBL] [Abstract][Full Text] [Related]
38. Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.
Schmohl M; Gansser D; Moschetti V; Stangier J
Thromb Res; 2015 Mar; 135(3):532-6. PubMed ID: 25600440
[TBL] [Abstract][Full Text] [Related]
39. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Douketis J; Bell AD; Eikelboom J; Liew A
Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
[TBL] [Abstract][Full Text] [Related]
40. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.
Vedovati MC; Germini F; Agnelli G; Becattini C
Chest; 2015 Feb; 147(2):475-483. PubMed ID: 25211264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
